MAPT and Alzheimer disease: Plasma p-tau181 also allows to discriminate AD from other neurodegenerative disorders, with an accuracy similar to that of tau PET and CSF p-tau181 (59), and identifies AD across the clinical continuum with gradual increase: from the lowest concentrations in Aβ negative young adults and cognitively unimpaired older adults, through higher concentrations in the Aβ positive cognitively unimpaired older adults and MCI groups, to the highest concentration in the Aβ positive MCI and AD groups (60).